BRD9 and cancer: We could confirm mis-splicing (Supplementary Fig. 6d) and downregulation (Supplementary Fig. 6e) of BRD9 in SF3B1-mutated cancers, but neither mis-splicing nor downregulation of BRD9 was detected for ASB-CLL (Supplementary Fig. 6f, g).